Protective role of melatonin in progesterone production by human luteal cells
Protective role of melatonin in progesterone production by human luteal cells
复制标题
DOI：
10.1111/j.1600-079x.2011.00878.x
复制
发表时间：
2011-09-01
影响因子：
10.3
通讯作者：
Sugino, Norihiro
中科院分区：
文献类型：
--
作者：
Taketani, Toshiaki;Tamura, Hiroshi;Sugino, Norihiro
本研究探讨了褪黑激素是否作为一种抗氧化剂保护黄体化颗粒细胞免受活性氧（ROS）的侵害，从而提高排卵期间卵泡中黄体酮的产生。在接受体外受精和胚胎移植（IVF-ET）的妇女取卵时取样卵泡液。卵泡液中褪黑素浓度与孕酮浓度呈正相关（r = 0.342, P < 0.05），与氧化应激标志物8-羟基-2′-脱氧鸟苷（8-OHdG）浓度呈负相关（r = -0.342, P < 0.05）。孕酮与8-OHdG浓度呈负相关（r = -0.246, P < 0.05）。在接受IVF-ET的妇女的卵母细胞提取时获得黄体化颗粒细胞。细胞用H2O2（30、50、100 μ m）在褪黑素（1、10、100 μ g/mL）存在或不存在的情况下孵育。H2O2显著抑制黄体化颗粒细胞产生黄体酮。褪黑素治疗克服了H2O2的抑制作用。在下一个治疗周期中，有黄体期缺陷（黄体中期血清黄体酮浓度< 10 ng/mL）的25例患者被分为两组：14名妇女在整个黄体期给予褪黑素（3 mg/天，22:00小时），11名妇女不给予任何药物作为对照。褪黑素治疗改善了14名女性中9名（64.3%）的血清黄体酮浓度（黄体中期10 ng/mL），而在对照组中，11名女性中只有2名（18.1%）的血清黄体酮水平正常。综上所述，褪黑激素可以保护卵泡中发生黄体生成的颗粒细胞免受ROS的影响，并有助于排卵期间黄体生成。
This study investigated whether melatonin protects luteinized granulosa cells from reactive oxygen species (ROS) as an antioxidant to enhance progesterone production in the follicle during ovulation. Follicular fluid was sampled at the time of oocyte retrieval in women undergoing in vitro fertilization and embryo transfer (IVF-ET). Melatonin concentrations in the follicular fluid were positively correlated with progesterone concentrations (r = 0.342, P < 0.05) and negatively correlated with the concentration of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidative stress marker (r = -0.342, P < 0.05). The progesterone and 8-OHdG concentrations were negatively correlated (r = -0.246, P < 0.05). Luteinized granulosa cells were obtained at the time of oocyte retrieval in women undergoing IVF-ET. Cells were incubated with H2O2 (30, 50, 100 mu m) in the presence or absence of melatonin (1, 10, 100 mu g/mL). Progesterone production by luteinized granulosa cells was significantly inhibited by H2O2. Melatonin treatment overcame the inhibitory effect of H2O2. Twenty-five patients who had luteal phase defect (serum progesterone concentrations < 10 ng/mL during the mid-luteal phase) were divided into two groups during the next treatment cycle: 14 women were given melatonin (3 mg/day at 22: 00 hr) throughout the luteal phase and 11 women were given no medication as a control. Melatonin treatment improved serum progesterone concentrations (> 10 ng/mL during the mid-luteal phase) in nine of 14 women (64.3%), whereas only two of 11 women (18.1%) showed normal serum progesterone levels in the control group. In conclusion, melatonin protects granulosa cells undergoing luteinization from ROS in the follicle and contributes to luteinization for progesterone production during ovulation.